Literature DB >> 20941707

Asymmetric amyloid fibril elongation: a new perspective on a symmetric world.

Caryn L Heldt1, Shuqi Zhang, Georges Belfort.   

Abstract

Amyloids are insoluble, fibrous proteins formed through the aggregation of misfolded proteins. They accumulate in the tissue of individuals with degenerative diseases, such as Parkinson's and Alzheimer's. The purpose of this study was to determine whether fibril growth from an initial model fibril seed is unidirectional or bidirectional. The prevailing theory on amyloid formation is that a symmetric fibril elongates equally from both ends. This study provides evidence to the contrary; the process occurs predominately unidirectionally, demonstrating that amyloid fibrils may be asymmetric and propagate mostly in one direction. Alexa Fluor 568 labeled insulin fibrils were seeded into a native insulin solution and allowed to elongate at 65°C while the kinetics of fibril growth was monitored. The resulting elongated fibrils were labeled with thioflavin-T, and the fluorescent images of the fibrils show that a majority of the elongated fibrils propagated along only one end of the seed, with the remaining labeled fibrils having bidirectional elongation or no elongation. Using a crystallographic model, we offer a structural explanation for asymmetric growth of the insulin fibrils. Thus, instead of the current view that fibrils grow symmetrically from both ends of the fibril, this is the first evidence that insulin amyloid fibrils formed in solution are asymmetric and appear to grow from only one end.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20941707     DOI: 10.1002/prot.22861

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  9 in total

1.  A generic crystallization-like model that describes the kinetics of amyloid fibril formation.

Authors:  Rosa Crespo; Fernando A Rocha; Ana M Damas; Pedro M Martins
Journal:  J Biol Chem       Date:  2012-07-05       Impact factor: 5.157

2.  Isolating toxic insulin amyloid reactive species that lack β-sheets and have wide pH stability.

Authors:  Caryn L Heldt; Dmitry Kurouski; Mirco Sorci; Elizabeth Grafeld; Igor K Lednev; Georges Belfort
Journal:  Biophys J       Date:  2011-06-08       Impact factor: 4.033

Review 3.  Protein nanofibrils and their use as building blocks of sustainable materials.

Authors:  Christofer Lendel; Niclas Solin
Journal:  RSC Adv       Date:  2021-12-08       Impact factor: 4.036

4.  Macrocyclic β-sheet peptides that inhibit the aggregation of a tau-protein-derived hexapeptide.

Authors:  Jing Zheng; Cong Liu; Michael R Sawaya; Balraju Vadla; Shafiullah Khan; R Jeremy Woods; David Eisenberg; Warren J Goux; James S Nowick
Journal:  J Am Chem Soc       Date:  2011-02-14       Impact factor: 15.419

5.  Evaluating nuclei concentration in amyloid fibrillation reactions using back-calculation approach.

Authors:  Mirco Sorci; Whitney Silkworth; Timothy Gehan; Georges Belfort
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

Review 6.  Nanoparticles in relation to peptide and protein aggregation.

Authors:  Masihuz Zaman; Ejaz Ahmad; Atiyatul Qadeer; Gulam Rabbani; Rizwan Hasan Khan
Journal:  Int J Nanomedicine       Date:  2014-02-12

7.  Patterning nanofibrils through the templated growth of multiple modified amyloid peptides.

Authors:  Hiroki Sakai; Ken Watanabe; Fuki Kudoh; Rui Kamada; Yoshiro Chuman; Kazuyasu Sakaguchi
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

8.  De novo designed protein inhibitors of amyloid aggregation and seeding.

Authors:  Kevin A Murray; Carolyn J Hu; Sarah L Griner; Hope Pan; Jeannette T Bowler; Romany Abskharon; Gregory M Rosenberg; Xinyi Cheng; Paul M Seidler; David S Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-15       Impact factor: 12.779

Review 9.  Misfolding of amyloidogenic proteins and their interactions with membranes.

Authors:  Annalisa Relini; Nadia Marano; Alessandra Gliozzi
Journal:  Biomolecules       Date:  2013-12-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.